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Nonhuman primate models of asthma
 
Robert L. Coffman and Edith M. Hessel
 
Asthma is a complex human disease that does not have an accurate 
counterpart in any common model organism. Most of our understanding of the 
immune mechanisms underlying asthma comes from studies in man and mouse. 
However, there are fundamental differences between the spontaneous disease 
in man and the experimentally induced counterparts in mice. We advocate 
more extensive use of nonhuman primate asthma models to reconcile these 
differences between man and mouse.
 
The past decade has seen dramatically
increased use of mouse models of allergic
asthma to study the fundamental immu-
nologic causes of the disease, as con-
trasted to the pharmacologic or physio-
logic consequences, and to identify and
test novel therapeutic strategies (1, 2).
This increased focus has not been with-
out controversy (3), and there are am-
ple reasons for caution in extrapolating
the findings in experimentally induced
mouse models to the naturally occurring
human disease. The fundamental immu-
nologic abnormality of both human aller-
gic asthma and mouse models is an in-
appropriate, poorly controlled T helper
type 2 (Th2) response to one or more
airborne allergens. There are, however,
important differences between the two
species, including techniques for mea-
suring pulmonary function, chronicity
of the disease process, and species differ-
ences in expression of, or responses to,
key cytokines and mediators (2). Large
animal models of asthma have been de-
veloped in dogs (4), sheep (5), and
monkeys (principally rhesus and cyno-
molgus macaques) (6–11). All have
proven useful for studies of pharmacol-
ogy and physiology and for preclinical
development of drugs that provide symp-
tomatic relief for asthma. We contend,
however, that monkey models are the
most suitable for studying immune reg-
ulation and effector functions in asthma
and for evaluating novel immunomod-
ulatory therapies. There are two basic
reasons for this assertion: first, the “tool-
box” for the analysis of immune re-
sponses in primates is far more complete
than in dogs or sheep. Second, novel
therapeutic agents, especially biologics
such as antibodies, cytokines, and nucleic
acids that specifically target the human
immune system, are much more likely
to be active in other primates than in
animals less genetically similar to man.
The goal of this commentary is to
highlight monkey models of allergic
asthma and to suggest their use as a
bridge between mouse models and hu-
man asthma.
 
Monkey models of allergic asthma
 
Nearly 40 years ago researchers began
to use rhesus monkeys (
 
Macaca mulatta
 
)
sensitized to the intestinal helminth
parasite 
 
Ascaris suum
 
 to study allergen-
induced immediate asthmatic responses
in the airways (6). A majority of pri-
mates caught in the wild demonstrate
skin test sensitivity to soluble extracts of
 
Ascaris
 
 (12), presumably from prior natu-
ral exposure to 
 
Ascaris suum
 
 or a related
parasite (13). As with most helminth
parasites, 
 
Ascaris
 
 exposure of monkeys
evokes a strong Th2-biased T cell mem-
ory response and increased levels of IgE
(12, 14). Subsequent airway challenge
of sensitized monkeys with 
 
Ascaris
 
 ex-
tracts results in both immediate and late
phase asthmatic reactions (6, 7), followed
by airway eosinophilia and hyperre-
sponsiveness (8). These responses are
comparable to those of atopic asthmatics
to an inhalation challenge with an appro-
priate allergen (15). The 
 
Ascaris
 
 model is
attractive because animals already appro-
priately sensitized can easily be identi-
fied. In addition, the “allergens” are not
common environmental antigens, and
exposure of the animals can be accu-
rately regulated and documented.
Other models for allergic asthma
have been developed in rhesus or cyno-
molgus monkeys using important human
allergens, including house dust mite (9–
11) and the birch pollen allergens, Bet
V1 and V2 (16). In general, animals
need to be deliberately sensitized with
these allergens, although spontaneous
allergic sensitization to dust mite and
cedar pollen occurs in monkeys (17).
These induced asthma models have
both advantages and disadvantages com-
pared with the 
 
Ascaris
 
 model. The major
advantage is control over the sensitization
process, permitting greater standardiza-
tion of the model and allowing research
into factors that prevent the onset of
allergic asthma. However, current proto-
cols are both time and labor intensive and
require repeated aerosol challenges (10,
11). The best characterized of these in-
duced models involves injection, fol-
lowed by repeated aerosol challenge of
house dust mite allergens (10).
The rationale for developing asthma
models in monkeys includes the
genetic and physiological similarity to
humans, the similarity of human and
monkey lungs in terms of anatomy,
histology, and ultrastructure, and their
size, which permits pulmonary func-
tion measurements and bronchoscopy
with techniques and instruments used
in human studies (10, 18, 19). Al-
though none of the primate models
represent the process of natural sensiti-
zation and frequent allergen exposure
that occurs in humans, many key features
of human allergic asthma are observed
(Table I). The responses to allergen
challenge in monkeys closely resemble
those in man in terms of both physio-
logical and immunological parameters.
Cohorts of sensitized primates are usually
maintained and challenged repeatedly
over several years, and develop impor-
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tant characteristics of chronic human
asthma, such as extensive airway re-
modeling (E.C.M. Martin, personal
communication; reference 20) and in-
creased baseline reactivity to metha-
choline (10).
 
Measuring lung function in monkeys
 
The ability to measure lung function in
similar ways in human and monkey
studies is a particular advantage. Al-
though spirometry is most often used in
humans, this technique is not suitable
for primates, as it requires subject coop-
eration. In primates the noninvasive
forced oscillation technique (7, 8, 21) is
the preferred techniques for measuring
changes in pulmonary function. This
technique superimposes forced oscilla-
tions onto normal spontaneous breath-
ing either at the airway opening or at
the body surface, and measures respec-
tively input or transfer impedance, from
which airway resistance and compliance
are calculated (21, 22). In humans, the
forced oscillation technique is used with
subjects unable to cooperate, such as
very young children, and for specific
research purposes (23). Madwed and
colleagues established that forced oscil-
lation in primates provides a consistent
method of quantifying airway responses
under baseline and bronchial challenge
conditions, and the responses observed
are similar to those in man, both in
healthy subjects and asthmatics (21).
This contrasts with the more indirect
measurements done in the mouse, such
as “enhanced pause” (Penh), which as-
sess functional parameters that are diffi-
cult to correlate with parameters af-
fected by human asthma, such as airway
resistance or forced expiratory volume
(3). Other techniques requiring anes-
thesia and/or mechanical ventilation
have also been used in monkey models
(11, 13, 24), and these also measure in-
dices of lung function similar to those in
man. Thus, the effects of immunomod-
ulatory agents on clinically relevant
lung functions may be easier to establish
in monkey than in mouse studies.
 
Immunological studies with monkey 
asthma models
 
The 
 
Ascaris suum
 
 model has been used
extensively for the preclinical evalu-
ation of asthma therapies, primarily
drugs for symptomatic intervention.
The published literature is incomplete,
as much of this work has been done by
pharmaceutical companies and remains
unpublished. Early work established
the effects of well-known antiallergy
and antiasthma medications in primates
and found them very similar to their
known effects in man (8), which sup-
ports the clinical relevance and predic-
tive value of testing pharmacological
agents in the primate asthma model.
Monkey asthma models have been
used in only a few cases to test inter-
ventions aimed at modifying the under-
lying Th2-biased immune response. Al-
though these studies were designed to
provide preclinical support for clinical
trials in man, they serve to demonstrate
the functional similarity of pulmonary
immune responses between monkey
and mouse models. In a series of pio-
neering studies, Wegner, Gundel, and
colleagues used monoclonal antibody
treatment of the 
 
Ascaris
 
 monkey model
to demonstrate that intercellular adhe-
sion molecule (ICAM)-1 (25) and en-
dothelial leukocyte adhesion molecule
(ELAM)-1 (26) were important for al-
lergen-induced cellular infiltration of
the airways. More recently, monoclonal
antibodies to human IL-5 (24) and IL-
13 (Dr. P.D. Monk, personal commu-
nication) have been shown to inhibit
airway responses to allergen challenge
in the 
 
Ascaris
 
 model, confirming earlier
demonstrations in mouse of the impor-
tance of these two cytokines. A differ-
ent type of immune modulator, a syn-
thetic CpG-containing oligonucleotide,
has also been shown to inhibit allergen
challenge responses and to slow or re-
verse the process of airway remodeling
in a house dust mite model (20). In-
deed, such preclinical development
studies provide most of our understand-
ing of the immune mechanisms in
 
Table I.
 
Comparison of principal features of human asthma and monkey asthma models
 
Human atopic asthma Monkey asthma models
 
Features of chronic disease
 
Allergen-specific IgE and skin test positivity
 
  
 
Eosinophils and IgE
 
 
 
 cells in airway
 
  
 
Th2 cells in airway
 
 
 
?
Mucous cell hyperplasia
 
  
 
Subepithelial fibrosis
 
  
 
Basement membrane thickening
 
  
 
Persistent baseline hyperreactivity to histamine or methacholine
 
  
 
Episodic wheezing and airflow obstruction
 
  
 
Bronchoconstriction triggered by nonatopic stimuli: e.g., cold air, exercise, viral infection
 
 
 
?
 
Response to inhaled allergen challenge
 
Th2-associated cytokine and chemokine induction
 
  
 
Migration of eosinophils, lymphocytes, and dendritic cells into airways
 
  
 
Early and late bronchoconstriction responses
 
  
 
Enhanced reactivity to histamine challenge
 
  
 
For monkey: 
 
 
 
, demonstrated in one or more monkey models; ?, not reported.
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monkey asthma models, as very few
studies have been done to characterize
the model, per se.
 
Reagents for primate immunology studies
 
One advantage of using primate versus
other large animal models for immu-
nology and asthma research is the ex-
tensive set of antibody-based reagents
available. Virtually all of these antibod-
ies were originally developed for detec-
tion of human molecules but have
significant cross-reaction with the
monkey orthologs. The NIH Nonhu-
man Primate Reagent Resource (http://
NHPreagents.bidmc.harvard.edu) has
been developed to facilitate access to
existing reagents used in nonhuman
primate models and to develop new re-
agents. It is clear from this website and
catalogs of several major antibody ven-
dors that a large subset of anti–human
antibodies react efficiently and specifi-
cally with the corresponding monkey
antigens. As a consequence of this re-
agent availability and the immunologi-
cal characterization done in monkey
studies for simian immunodeficiency
virus infection and vaccination (27,
28), the cellular components of the
rhesus immune system have been quite
well defined and are known to be simi-
lar to subsets in man. Protocols have
been developed to isolate various sub-
sets of dendritic cells (28) and T cells
(27), and the first characterization of
these important subsets in the airways
has been reported (29).
The crossover to macaques of hu-
man nucleic acid–based reagents is
even more extensive than those of
protein and antibody-based reagents.
Thus, widely used probes such as PCR
primers, microarrays, and small inter-
fering RNAs designed from human
gene sequence data can be applied to
monkey studies. This is predictable
from the 
 
 
 
95% sequence identity of
human and rhesus genes. Our experi-
ence with quantitative PCR measure-
ments of mRNA levels suggests that
 
 
 
90% of primer pairs designed from
human sequences work with the same
efficiency and specificity in both rhesus
(29) and cynomolgus (unpublished
data) monkeys. Similarly, microarrays
of human sequences, human oligonu-
cleotides, or cDNAs are quite useful
(30, 31), although data for a small
number genes will be inaccurate or ab-
sent. The ongoing rhesus monkey
genome project (the first draft was
released in January 2005; http://www.
hgsc.bcm.tmc.edu/projects/rmacaque)
promises to fill the remaining gaps
in our set of gene-based monkey
reagents.
 
Why use monkeys instead of 
mice or humans?
 
The response of atopic individuals to
inhaled allergens is a complex, ordered
interplay of mediators, cytokines, and
cell migrations throughout the respira-
tory tract and draining lymph nodes
and blood. The primary experimental
design used in both human and animal
studies of this response is acute chal-
lenge with an antigen solution that is
either nebulized or delivered by in-
tratracheal or intranasal administra-
tion. Allergen-induced changes in lung
function are assessed by a variety of
noninvasive techniques; however,
changes in immune functions require
invasive methods of sampling. In man
and larger animals this is usually done
by bronchoscopy with bronchial lavage
or biopsy, whereas mice are virtually
always killed for lung and lymph node
harvest. Peripheral blood has little util-
ity for measuring immune responses to
pulmonary challenge in man (32), and
minimally invasive techniques for sam-
pling the respiratory tract, such as in-
duced sputum (33) and exhaled cyto-
kine measurements (34), are technically
challenging and limited in scope. This
imposes significant limitations for mech-
anistic studies in man. Few patients will
agree to repeated cycles of allergen
challenge and bronchoscopy, and there
are growing ethical and regulatory con-
straints on the use of these techniques.
Furthermore, treatments in vivo can be
done only with approved drugs or ex-
perimental drugs under an Investiga-
tional New Drug application.
Nonhuman primate asthma models
permit many of the experimental ma-
nipulations performed in mice but in a
model much closer to chronic human
asthma in terms of immunology, physi-
ology, and histopathology. The limited
data available show that changes in im-
mune parameters in response to inhaled
allergen challenge in the monkey 
 
As-
caris
 
 model (7, 8, 35) are largely indis-
tinguishable from those observed when
human asthmatics are similarly chal-
lenged (Table I) (15). The patterns of
cellular infiltration into the bronchoal-
veolar lavage and the increases in Th2
cell–associated cytokines and chemo-
kines are similar in both models and are
quite comparable to responses in the
mouse (1). We have recently found a
striking similarity between human and
monkey allergen challenges in terms of
infiltration of dendritic cell subsets and
increases in expression of a panel of
over 50 allergy-related genes (unpub-
lished data). Thus, at many levels of
comparison there is substantial similar-
ity between atopic humans and mon-
keys in terms of the immune responses
and physiological consequences of acute
allergen challenge.
Several other types of monkey
asthma studies have the potential to fill
significant gaps in our understanding of
human asthma. For example, the harvest
of organs from experimental animals for
detailed study of pathology, histology,
immune function, and gene expression
has been used to great advantage in re-
cent work from Plopper, Hyde, and
colleagues (29, 31, 36). Such studies
provide insights largely unobtainable
from human studies, which rely on lim-
ited biopsy samples or on autopsy ma-
terials. Captive breeding colonies of
rhesus and cynomolgus monkeys also
offer opportunities to study the develop-
ment and possible prevention of atopy
and asthma during childhood—research
that cannot be readily done in mouse or
man. It is now clear that a wide range of
environmental factors, superimposed on
genetic background, determine the oc-
currence and severity of allergy and
asthma (37). Allergen exposures and in-
fections during the first few years of life,
when both the respiratory tract and the
immune system are developing rapidly,
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are particularly important (38). Most of
our understanding of the development
of allergy and asthma in children comes
from large epidemiological studies;
however, few of these have provided
correlations of clinical phenotype with
sophisticated measures of immune func-
tions (39, 40). Possibilities for experi-
mental intervention to confirm such
correlations are very limited for obvious
reasons of safety and ethics. The recent
demonstration that allergen-specific im-
munotherapy can halt the progression of
allergic rhinitis to asthma has shown the
promise of early intervention (41); how-
ever, this study was only possible be-
cause this form of immunotherapy is an
accepted practice in children with aller-
gies. Mouse models are of very limited
use; the physiological state of both the
immune system and the lung at birth are
very different in mice and primates, and
development to an adult state occurs in
a matter of weeks in mice, not years as
in humans. Mechanistic studies in co-
horts of neonatal monkeys would not be
inexpensive, but they would offer a
unique opportunity to study the mecha-
nisms of key risk factors and to evaluate
new approaches to the prevention rather
than the treatment of asthma.
In summary, we regard monkey
asthma models as having substantial un-
tapped potential to help us understand
the mechanisms of chronic immune
dysfunction in asthma and to explore
new therapeutic approaches based on
that understanding. For many reasons,
not the least of which is cost, they can-
not replace mouse studies, but monkey
models have developed to the point
that they can allow researchers to con-
firm their findings in a species much
more like man, before entering even
more costly human studies.
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